TABLE 2.

Graft outcome in included cohort and single-arm studies.

		Graft loss							Graft survival
Study	Study design	Total graft loss	Plasma exchange	Either tacrolimus or cyclosporine, shift to sirolimus (%)	Acute antibody-mediated rejection (%)	Acute cell-mediated rejection (%)	C4d+	C4d− (%)	1-year survival (%)	2-year survival (%)	3-year survival (%)	4-year survival (%)	5-year survival (%)	8-year survival (%)	10-year survival (%)
Baid, 1999 [33]	Single-arm								40
Braet, 2016 [34]	Single-arm								32
Caires, 2012 [35]	Single-arm											43
Costa, 2013 [49]	Single-arm								73.30
Dessaix, 2019 [36]	Single-arm								8
Doradla, 2020 [37]	Single-arm	53% (9/17)			100	100			47				35		35
Fortin, 2004 [38]	Single-arm	30.77% (4/13)
Gumber, 2014 [41]	Single-arm	17.65% (6/34)
Le Quintrec, 2008 [50]	Single-arm	33.33% (8/24)							67
Meehan, 2011 [51]	Single-arm						57%
Oyen, 2006 [45]	Single-arm	28.57% (2/7)		28.6
Ozedemir, 2018 [46]	Single-arm								83	51			51
Reynolds, 2003 [3]	Cohort								47	35
Santos, 2003 [47]	Single-arm	33.33% (2/6)
Satoskar, 2010 [16]	Single-arm	40.68% (24/59)	35% (8/23)				40%	42
Tasaki, 2019 [17]	Cohort	26.67% (4/15)
Wu, 2016 [52]	Cohort								70.0	48.3				28.0
Zarifian, 1999 [48]	Single-arm								81		69